Sulforaphane (broccoli sprout extract) trials recruiting now
4 registrations that name sulforaphane as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 4 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 4 registrations
RecruitingNCT07040280
Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma
Phase 2
ECOG-ACRIN Cancer Research Group
About 120 people
Started Feb 20, 2026
In plain words A Phase 2 study of sulforaphane in people 18 and older, run by ECOG-ACRIN Cancer Research Group. It plans to enroll about 120 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Clinical Stage 0 Cutaneous Melanoma AJCC v8; Clinical Stage I Cutaneous Melanoma AJCC v8; Clinical Stage II Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Cutaneous Dysplastic Nevus.
Patient must have ≥ 3 clinically atypical nevi, assessed within 30 days prior to randomization, that are consistent with the International Agency for Research on Cancer (IARC) definition as follows.
Must have a diameter of ≥ 5mm in one dimension
Must include a macular component in at least one area
Must have at least two of the following features: ill-defined borders, color variegation, uneven contour, and erythema NOTE: Lesions suspicious for incipient melanoma will be removed and are not intended for the study
13 more inclusion criteria and the exclusion criteria are on the listing.
This phase II trial tests how well sulforaphane works in preventing melanoma in patients with multiple atypical moles (nevi) and a prior history of melanoma. Patients with a history of melanoma and multiple atypical nevi are at a significantly increased risk of developing additional melanomas than those without atypical nevi. Prevention measures usually include sun protection, monthly skin self-examinations and regular skin examinations from a doctor. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT03934905
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
Phase 1 and 2
Texas Tech University Health Sciences Center
About 70 people
Started Jun 1, 2022
In plain words A Phase 1 and 2 study of sulforaphane in people 18 to 89, run by Texas Tech University Health Sciences Center. It plans to enroll about 70 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 89. Conditions: Anthracycline Related Cardiotoxicity in Breast Cancer.
Age 18 to 89 years
No prior diagnosis of coronary artery, carotid artery or peripheral artery disease
Not pregnant or breastfeeding (urine pregnancy test will be done if female of childbearing potential)
Breast cancer requiring treatment with DOX-containing regimen above
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
sulforaphane; Placebo Oral Tablet
Registered summary
Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function. Recent advancements have increased cancer survivorship but it remains clinically challenging to mitigate the cardiotoxic side effects. Although there are several strategies used to reduce the occurrence and severity of DOX-induced cardiotoxicity, they are not particularly effective. Hence, there is an urgent need to develop new strategies that prevent the cardiotoxic effects of DOX but maintain its potency as a cancer therapy. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07297576
Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
No phase
Institute of Hematology & Blood Diseases Hospital, China
About 36 people
Started Oct 22, 2025
In plain words A study of sulforaphane in people 18 and older, run by Institute of Hematology & Blood Diseases Hospital, China. It plans to enroll about 36 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: ALL (Acute B-Lymphoblastic Leukemia); AML (Acute Myelogenous Leukemia; MDS (Myelodysplastic Syndrome).
Patients with high-risk haematological malignancies: including AML, ALL, high-risk MDS
Age: ≥18 years
Karnofsky score ≥70%, Eastern Cooperative Oncology Group (ECOG) physical status ≤2 points
Selection of non-haematopoietic cord blood: donor-recipient HLA high-resolution compatibility ≥4/6, 7/10 and CD34 cells ≥0.83×105/kg (recipient's body weight), meeting the above criteria, only cord blood with a freezing time of ≥10 years…
The exclusion criteria are on the listing.
What it tests, as registered
Sulforaphane
Registered summary
Umbilical cord blood (UCB) is rich in haematopoietic stem progenitor cells and immune cells, and is used for transplantation for a variety of haematological disorders with the advantages of low mating requirements and fewer transplant complications. By March 2025 China's seven (eight) public cord blood stem cell banks had frozen more than 280,000 public umbilical cord blood, while the percentage of those frozen for ≥10 years was 26%, making clinical application a concern. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07652866
Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia
No phase
Second Xiangya Hospital of Central South University
About 60 people
Starts Jun 2, 2026 (estimated)
In plain words A study of sulforaphane in people 12 to 45, run by Second Xiangya Hospital of Central South University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 12 to 45. Conditions: Schizophrenia Disorder.
Diagnosis of schizophrenia according to DSM-5 criteria.
First-episode or illness duration ≤ 10 years, but currently in a non-acute phase of schizophrenia.
Negative symptoms present for ≥ 6 months prior to study entry. Patients must be outpatients or hospitalized for social reasons rather than symptom exacerbation.
PANSS negative subscale (7 items) total score ≥ 20; at least one negative item score > 3; no change > 3 points between screening and baseline.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Placebo; Sulforaphane
Registered summary
The goal of this randomized, double-blind, placebo-controlled clinical trial with an open-label extension is to evaluate whether sulforaphane can improve negative symptoms and cognitive impairment, and to explore its underlying mechanisms in patients with schizophrenia (aged 12-45 years, both sexes, stable on antipsychotic medication). The study duration includes 12 weeks of double-blind treatment followed by a 12-week open-label extension. The full summary is on the listing.